“…These data allow production in advance, reuse of nonadministered preparations, and product savings. These stabilities concern the following products: 14 days for aflibercept, 3 90 days for atezolizumab, 4 28 days for cabazitaxel, 25,26 28 days for carfilzomib, 31 90 days for cetuximab, 35 28 days for daratumumab administered subcutaneously, 48 28 days for a durvalumab vial with a Spike device, 58 30 days for ipilimumab, 80,81 14 days for lurbinectedin, 84 10 days for a nivolumab vial with a Spike device, 96 14 days for omacetaxin, 97 7 days for paclitaxel albumin, 101 14 days for pembrolizumab, 102,103 28 days for pemetrexed diarginine, 105 14 days for pevonedistat, 107 and 21 days for trabectedin in a glass vial. 113…”